Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 118Neoplasms 110Lung Neoplasms 65Colorectal Neoplasms 52Prostatic Neoplasms 46Carcinoma, Non-Small-Cell Lung 46Pancreatic Neoplasms 34Melanoma 33Ovarian Neoplasms 29Neoplastic Cells, Circulating 29Head and Neck Neoplasms 27Uterine Cervical Neoplasms 23Multiple Myeloma 20Glioma 20Colonic Neoplasms 20Carcinoma, Hepatocellular 20Sarcoma 19Leukemia, Myeloid, Acute 18Neoplasm Metastasis 17Lymphoma 15Glioblastoma 15Esophageal Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Hematologic Neoplasms 14Endometrial Neoplasms 14Leukemia 13Myelodysplastic Syndromes 11Kidney Neoplasms 11Gastrointestinal Neoplasms 11Carcinoma, Renal Cell 11

Interventions

cabozantinib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
High Grade Neuroendocrine Neoplasms × Blood Specimen Collection × Clear all
NCT04412629 2026-04-06

Cabozantinib in High Grade Neuroendocrine Neoplasms

Washington University School of Medicine

Phase 2 Active not recruiting
35 enrolled
Endocrine

High Grade Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡